Dantrolene Shortage: What Providers and Prescribers Need to Know in 2026

Dantrolene Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling their Dantrolene prescriptions, you're hearing a real and persistent problem. While oral dantrolene sodium is not on the FDA's active shortage list, localized availability gaps continue to affect patients across the country. This briefing covers what you need to know to counsel your patients effectively and optimize their access.

Complete Timeline: How We Got Here

1974: Dantrium (dantrolene sodium) oral capsules receive FDA approval for chronic muscle spasticity. Initially marketed by Norwich Eaton Pharmaceuticals.

1979: FDA approves Dantrium Intravenous for the treatment and prevention of malignant hyperthermia, establishing dantrolene as the only approved therapy for MH.

1991: Black Box Warning added to oral Dantrium labeling for hepatotoxicity, including fatal hepatitis. Risk factors identified: doses >200 mg/day, duration >60 days, females, patients over 35, concurrent hepatotoxic medications.

2014: Ryanodex (dantrolene sodium injectable suspension, 250 mg/vial) approved by FDA. Manufactured by Eagle Pharmaceuticals, it offered a more concentrated formulation requiring less reconstitution time — critical in MH emergencies.

2018–2022: Intermittent supply disruptions of injectable dantrolene products reported by ASHP. Multiple manufacturers affected. Hospitals and surgical centers flagged concerns about maintaining adequate emergency stock.

2023–2026: Injectable supply has stabilized with four approved products on the market (Dantrium IV, Revonto, Ryanodex, and Hikma generic). Oral supply remains generally adequate at the wholesale level, though retail pharmacy stocking remains inconsistent.

Current Availability Landscape for Prescribers

Supply Chain Status

Generic dantrolene sodium oral capsules (25 mg, 50 mg, 100 mg) are available from multiple manufacturers through major wholesalers. At the system level, supply is adequate. The challenge is at the last mile — individual pharmacy stocking decisions.

Prior Authorization Complexity

Generic oral dantrolene is typically covered as a Tier 1 or Tier 2 generic on most commercial and Medicare formularies. Prior authorization is generally not required for the oral form. However, some managed care plans may require documentation of:.

• Diagnosis of an upper motor neuron disorder
• Trial and failure of first-line agents (Baclofen, Tizanidine)

Brand-name Dantrium may require step therapy or prior authorization on some plans.

Indication-Specific Considerations

For spasticity management, most insurers cover oral dantrolene without significant barriers. For malignant hyperthermia prophylaxis in susceptible patients undergoing surgery, the preoperative oral regimen is well-established and coverage is straightforward. The injectable forms are covered under the medical benefit for acute MH treatment.

The Real-World Availability Picture

Supply Chain Mechanics

Dantrolene follows the standard manufacturer → wholesaler → pharmacy distribution chain. Because it's a lower-volume medication, many retail pharmacies — particularly chain locations — do not maintain standing stock. Instead, they order on demand, which can create 1–3 day delays for patients.

Dose-Specific Variation

Availability can vary by strength. The 25 mg capsule (the starting dose) tends to be the most widely available. The 100 mg capsule — the maintenance dose for many patients — may be less consistently stocked since fewer pharmacies carry the higher-dose capsule in quantity.

Regional Disparities

Availability tends to be better in areas with higher concentrations of neurology clinics, rehabilitation centers, and academic medical centers. Rural and underserved areas may have fewer pharmacy options stocking Dantrolene.

Cost and Access: The Numbers Your Patients Are Seeing

• Retail (cash) price: $50–$200/month for generic dantrolene sodium depending on dose and quantity
• With coupons (GoodRx/SingleCare): As low as $22–$30 for a 30-day supply
• Insurance copay: $5–$25/month (Tier 1–2 generic)
• Manufacturer savings: No active copay card or manufacturer program for oral generic dantrolene
• Patient assistance: NeedyMeds, RxAssist, and state pharmaceutical assistance programs may help uninsured patients

Tools and Resources for Your Practice

• Medfinder Provider Portal — Search for pharmacies with Dantrolene in stock on behalf of your patients. Medfinder's team contacts pharmacies to verify availability.
• FDA Drug Shortage Database — Monitor official shortage status for both oral and injectable dantrolene formulations
• ASHP Drug Shortage Resource Center — Provides detailed shortage updates, estimated resupply dates, and clinical alternatives
• NeedyMeds (needymeds.org) — Database of patient assistance programs for uninsured/underinsured patients

Looking Ahead

Several trends are worth watching in the Dantrolene market:

• Generic competition: Continued entry of generic manufacturers should further stabilize oral supply and may help reduce pricing
• Injectable market stability: Four approved injectable products now serve the hospital market, reducing the risk of future MH treatment shortages
• Practice evolution: Growing use of intrathecal baclofen and targeted botulinum toxin injections for severe spasticity may shift some demand away from oral dantrolene
• Drug pricing legislation: Ongoing state and federal efforts to increase pricing transparency may benefit patients paying cash for generic dantrolene

Final Thoughts

Dantrolene remains a valuable tool in spasticity management — particularly for patients who don't tolerate centrally-acting agents or need the unique peripheral mechanism. As prescribers, the most impactful step you can take is directing patients to tools that streamline pharmacy access.

The Medfinder provider portal lets you search on behalf of patients during the visit, eliminating the frustrating pharmacy-to-pharmacy calling that leads to treatment delays and missed doses.

Related resources:

• How to Help Your Patients Find Dantrolene in Stock: A Provider's Guide
• How to Help Your Patients Save Money on Dantrolene
• Share this patient-facing update: Dantrolene Shortage Update for Patients